Cargando…

Anti‐TNFα induced lupus due to infliximab therapy in a patient with concurrent Crohn's disease

Anti‐TNFα inhibitor‐induced Lupus (ATIL) is a rare syndrome characterized by a wide array of symptoms ranging from skin manifestations to organ‐specific symptoms such as pleural effusions, pericardial effusions, hepatotoxicity, etc. Infliximab is implicated in most cases, and ATIL usually develops b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Akanksha, Ahmed, Taha, Mehta, Aashna, Birnbaum, Julius, Shrestha, Abhigan Babu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354357/ https://www.ncbi.nlm.nih.gov/pubmed/37476595 http://dx.doi.org/10.1002/ccr3.7673

Ejemplares similares

Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease
por: Steenholdt, Casper, et al.
Publicado: (2016)

Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease
por: Kamel, Amir Y., et al.
Publicado: (2016)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

An interesting case of pulmonary hypertension in nephrotic syndrome due to amphetamine use for attention-deficit hyperactivity disorder
por: Khan, Abat, et al.
Publicado: (2023)

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease
por: Fonseca, Ashley, et al.
Publicado: (2021)

Concerns over cardiovascular manifestations associated with monkeypox immunization: a literature review
por: Shrestha, Abhigan Babu, et al.
Publicado: (2023)

Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease
por: Ye, Chenglin, et al.
Publicado: (2022)

Parallel Changes in Harvey-Bradshaw Index, TNFα, and Intestinal Fatty Acid Binding Protein in Response to Infliximab in Crohn's Disease
por: Al-Saffar, Anas Kh., et al.
Publicado: (2017)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn’s Disease
por: Naseer, Maliha, et al.
Publicado: (2017)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

Exploring the possible therapeutic role of influenza vaccine in chronic kidney disease patients
por: Shrestha, Abhigan B., et al.
Publicado: (2023)

Anti-TNF-α Therapies in Systemic Lupus Erythematosus
por: Zhu, Lang-Jing, et al.
Publicado: (2010)

Anti-TNF-α and hydralazine drug-induced lupus
por: Quaresma, Maria Victória, et al.
Publicado: (2015)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Regulatory T cells in Crohn's disease following anti‐TNF‐α therapy
por: Chiba, Toshimi, et al.
Publicado: (2019)

Erratum: Transmembrane TNF-α Density, But Not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Anti‐tumour necrosis factor‐α‐induced lupus in a patient receiving infliximab for sarcoidosis
por: Stranks, Lachlan, et al.
Publicado: (2022)

Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab
por: Chimenti, Maria Sole, et al.
Publicado: (2013)

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar
por: Buurman, D. J., et al.
Publicado: (2018)

Anti-TNF Therapy in Crohn’s Disease
por: Adegbola, Samuel O., et al.
Publicado: (2018)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Paradoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn’s disease
por: Amano, Hitoshi, et al.
Publicado: (2017)

Polymorphism at the position -308 of TNF-α gene influences outcome of infliximab therapy in rheumatoid arthritis
por: Mugnier, B, et al.
Publicado: (2004)

Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses
por: Fujita, Shunsuke, et al.
Publicado: (2022)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease
por: Kashima, Shin, et al.
Publicado: (2022)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

The TNF-α -308 polymorphism may affect the severity of Crohn's disease
por: Santana, Genoile, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k7frb39o1readdvb9gff6gnfe2